Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Renerve Limited ( (AU:RNV) ) has issued an announcement.
ReNerve Limited has reported strong sales growth following its recent IPO and ASX listing, raising A$7 million. The company is expanding its sales of the NervAlign® Nerve Cuff in the US market and has secured new distribution agreements in Hong Kong, Macau, and the Middle East. ReNerve is conducting a clinical study on its NervAlign® Nerve Cuff, with results expected in Q3 FY25, and aims to develop additional peripheral nerve injury products over the next four years. The company had a strong cash position of $6.4 million as of December 31, 2024.
More about Renerve Limited
ReNerve Limited is an Australian biotechnology company focused on developing innovative products for peripheral nerve injury repair. The company is primarily known for its NervAlign® Nerve Cuff, which is used in surgeries for repairing damaged or transected nerves and has received FDA clearance. ReNerve is actively expanding its market presence, particularly in the US, and has established distribution agreements in Hong Kong and the Middle East.
YTD Price Performance: -25.71%
Average Trading Volume: 370,446
Find detailed analytics on RNV stock on TipRanks’ Stock Analysis page.
